期刊
NATURE COMMUNICATIONS
卷 10, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-09438-w
关键词
-
资金
- Cancer Research UK [A14867, C20510, A13031]
- Cambridge Cancer Centre PhD Studentship
- BBSRC PhD studentship
- AstraZeneca-Cambridge Cancer Centre Collaborative Award
- Institute Strategic Programme Grants from BBSRC [BB/J004456/1, BB/P013384/1]
- AstraZeneca
- Wellcome Trust
- BBSRC [BBS/E/B/000C0434, BBS/E/B/000C0433, BBS/E/B/000C0417] Funding Source: UKRI
Acquired resistance to MEK1/2 inhibitors (MEKi) arises through amplification of BRAF(V600E) or KRAS(G13D) to reinstate ERK1/2 signalling. Here we show that BRAF(V600E) amplification and MEKi resistance are reversible following drug withdrawal. Cells with BRAF(V600E) amplification are addicted to MEKi to maintain a precise level of ERK1/2 signalling that is optimal for cell proliferation and survival, and tumour growth in vivo. Robust ERK1/2 activation following MEKi withdrawal drives a p57(KIP2_)dependent G1 cell cycle arrest and senescence or expression of NOXA and cell death, selecting against those cells with amplified BRAF(V600E). p57(KIP2) expression is required for loss of BRAF(V600E) amplification and reversal of MEKi resistance. Thus, BRAF(V600E) amplification confers a selective disadvantage during drug withdrawal, validating intermittent dosing to forestall resistance. In contrast, resistance driven by KRAS(G13D) amplification is not reversible; rather ERK1/2 hyperactivation drives ZEB1-dependent epithelial-to-mesenchymal transition and chemoresistance, arguing strongly against the use of drug holidays in cases of KRAS(G13D) amplification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据